Kranz Jennifer, Wagenlehner Florian M E, Steffens Joachim, Hakenberg Oliver W, Schneidewind Laila
Klinik für Urologie und Kinderurologie, St.-Antonius Hospital gGmbH, Eschweiler, Deutschland.
Universitätsklinik und Poliklinik für Urologie, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland.
Urologe A. 2021 May;60(5):610-616. doi: 10.1007/s00120-021-01461-4. Epub 2021 Feb 9.
Fournier's gangrene (FG) is a sporadic and life-threatening disease, but the outcome has not improved in recent years.
The primary aim of this study was the description of current practice patterns in German academic medicine. The secondary aim was the identification of factors associated with a higher mortality rate. Furthermore, the data will be used for the planning of a registry study.
A 29-item nonvalidated questionnaire was sent to German University Medical Centers (Department of Urology), including three reminders from April through June 2020. Data management and analysis were performed with SPSS 26.0.
The response rate was 88.9%. A median of 5 patients (median age 60.0 years) with FG were treated annually in German University Medical Centers. The contemporary practice patterns are very heterogeneous, especially in terms of empirical antibiotic treatment. Only one significant risk factor for a mortality rate higher than 20.0% was identified-intensive care treatment for ≥10 days (p = 0.039). In addition, 50% stated that outcome of FG has not improved in recent years. Furthermore, the majority of the respondents think that mortality is still too high. Consequently, 84.4% support a registry study. From the answers to the open questions we received a variety of suggestions for planning such a study, e.g., histological confirmation of the disease.
Treatment of FG is currently very heterogeneous. Furthermore, treatment outcomes are often unacceptable and difficult to predict.
福尼尔坏疽(FG)是一种散发且危及生命的疾病,但近年来其治疗结果并未得到改善。
本研究的主要目的是描述德国学术医学中的当前实践模式。次要目的是确定与较高死亡率相关的因素。此外,这些数据将用于规划一项注册研究。
向德国大学医学中心(泌尿外科)发送了一份包含29个条目的未经验证的问卷,在2020年4月至6月期间进行了三次提醒。使用SPSS 26.0进行数据管理和分析。
回复率为88.9%。德国大学医学中心每年治疗FG患者的中位数为5例(中位年龄60.0岁)。当前的实践模式非常不一致,尤其是在经验性抗生素治疗方面。仅确定了一个死亡率高于20.0%的显著风险因素——重症监护治疗≥10天(p = 0.039)。此外,50%的人表示近年来FG的治疗结果没有改善。此外,大多数受访者认为死亡率仍然过高。因此,84.4%的人支持进行一项注册研究。从对开放性问题的回答中,我们收到了关于规划此类研究的各种建议,例如疾病的组织学确认。
目前FG的治疗非常不一致。此外,治疗结果往往难以接受且难以预测。